An MRI Brain (With Contrast) is a non-invasive diagnostic imaging test that creates highly detailed pictures of the brain and nearby structures using a strong magnetic field and radio waves (no ionizing radiation, unlike a CT scan). “With contrast” means a contrast agent—most commonly a gadolinium-based dye—is injected into a vein during the exam to make certain tissues, blood vessels, inflammation, and abnormal growths easier to see on brain imaging.

This test does not measure “brain function” directly; instead, it shows the brain’s anatomy (structure) and highlights areas where the blood-brain barrier may be disrupted or where blood flow patterns differ. Contrast enhancement can help radiologists better define the size, borders, and activity of findings such as tumors, infection, inflammation, active multiple sclerosis plaques, or abnormal blood vessels.

Results are typically reported as normal (no concerning abnormalities) or abnormal with a description of the location and appearance of any findings. Common result terms include:

• “Enhancing lesion”: an area that takes up contrast, which can be seen with tumors, active inflammation, infection, or breakdown of the blood-brain barrier (the meaning depends on the pattern and clinical context).

• “Non-enhancing lesion”: may represent older injury/scar tissue, some types of tumors, prior stroke changes, or certain white matter changes.

• “Mass effect” or “midline shift”: a lesion is large enough to push on surrounding brain tissue—this can be urgent.

• “Edema”: swelling around a lesion, often seen with tumors, infection, or inflammation.

Your healthcare team interprets the MRI findings alongside symptoms, exam results, and other tests to decide whether follow-up imaging, medication, referral (e.g., neurology/neurosurgery), or biopsy is needed.

Doctors order an MRI of the brain with contrast when they need a clearer look at possible abnormalities than a non-contrast MRI or CT can provide. It is commonly used to evaluate new or worsening neurological symptoms and to investigate suspected conditions involving tumors, stroke complications, infection, inflammation, or blood vessel problems.

This test may be recommended if you have symptoms such as:

• Persistent or severe headaches, especially with new pattern, nighttime waking, or neurological changes

• Seizures (first-time seizure or change in seizure pattern)

• Weakness, numbness, facial droop, or speech trouble (possible stroke/TIA or other neurological disorder)

• Vision changes (blurred vision, double vision, visual field loss)

• Dizziness, loss of balance, or coordination problems

• Memory changes, confusion, personality change, or cognitive decline

• New neurological symptoms in pregnancy/postpartum or in people with autoimmune disease (as directed by a clinician)

It is also frequently used when there is clinical concern for:

• Brain tumors or metastases: contrast helps identify tumor tissue, define boundaries, and detect small lesions.

• Multiple sclerosis and other demyelinating disease: contrast can show whether plaques are “active” (new inflammation) versus older scarring.

• Infection (e.g., abscess, meningitis/encephalitis): contrast can highlight inflamed tissues and ring-enhancing abscesses.

• Vascular conditions: certain aneurysms, vascular malformations, venous thrombosis, or vascular inflammation may be better characterized with contrast sequences (sometimes paired with MRA/MRV).

• Follow-up or treatment monitoring: to track known lesions over time, evaluate response to therapy (e.g., cancer treatment), or assess post-surgical or post-radiation changes.

Safety considerations are important. Be sure to tell your imaging team if you have kidney disease, a history of contrast reaction, are pregnant, or have implanted devices (pacemaker, cochlear implant, aneurysm clips). Many modern implants are MRI-conditional, but they must be verified. Kidney function may be checked before giving a gadolinium contrast agent.

• Brain tumors (primary tumors such as glioma, meningioma; and metastatic tumors)
• Stroke and related complications (including subacute stroke assessment and hemorrhagic transformation evaluation as appropriate)
• Multiple sclerosis and other demyelinating disorders
• Brain infection (encephalitis, meningitis complications, brain abscess)
• Cerebral aneurysm and vascular malformations (e.g., arteriovenous malformation), often alongside MRA/MRV
• Cerebral venous sinus thrombosis (CVST)
• Inflammatory/autoimmune conditions affecting the brain (e.g., vasculitis, neurosarcoidosis)
• Traumatic brain injury complications (e.g., contusions, diffuse axonal injury assessment in select cases)
• Pituitary or sellar region lesions (when protocols include dedicated pituitary imaging)

• Clarifying the cause of unexplained neurological symptoms to support early diagnosis and treatment
• Detecting, staging, or monitoring brain tumors to guide care planning
• Assessing brain health after a suspected stroke or transient ischemic attack (TIA), when contrast-enhanced detail is needed
• Monitoring disease activity in multiple sclerosis or other inflammatory neurological disorders
• Evaluating suspected brain infection or inflammation to enable timely, targeted therapy
• Following known brain lesions over time (surveillance imaging) and checking response to treatment
• Supporting safer neurosurgical or radiation therapy planning by mapping lesion extent and enhancement patterns